APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
-2.89%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$3.01B
AUM Growth
+$3.01B
(-30%)
Cap. Flow
-$880M
Cap. Flow
% of AUM
-29.21%
Top 10 Holdings %
Top 10 Hldgs %
32.92%
Holding
106
New
21
Increased
16
Reduced
41
Closed
22
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
$97.9M |
| 2 |
Becton Dickinson
BDX
|
$71.3M |
| 3 |
Zoetis
ZTS
|
$67.8M |
| 4 |
Merck
MRK
|
$63.8M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$61.9M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
$218M |
| 2 |
argenx
ARGX
|
$128M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$125M |
| 4 |
Boston Scientific
BSX
|
$120M |
| 5 |
Neurocrine Biosciences
NBIX
|
$97.6M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Fate Therapeutics
FATE
$115M
| – | – |
-104,653
| Closed | -$1.06M |
|
102
Eli Lilly
LLY
$661B
| – | – |
-217,000
| Closed | -$79.4M |
|
|
103
Madrigal Pharmaceuticals
MDGL
$9.7B
| – | – |
-430,000
| Closed | -$125M |
|
104
Orchestra BioMed
OBIO
$147M
| – | – |
-400,000
| Closed | -$3.99M |
|
105
SCYNEXIS
SCYX
$35.4M
| – | – |
-1,140,600
| Closed | -$1.78M |
|
|
MSAC
106
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
| – | – |
-520,000
| Closed | -$5.24M |
|